TGFB1 and hepatocellular carcinoma: KLF2 can inhibit the transcriptional activity of SMAD2/3 and SMAD4 in the TGF-β/SMAD pathway, improving TGF-β-induced target gene expression and inhibiting tumor growth and migration in HCC (95).